Last update 08 May 2025

Etoposide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(−)-etoposide, 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside), 4-demethylepipodophyllotoxin β-D-ethylideneglucoside
+ [24]
Action
agonists, inhibitors
Mechanism
CUL4B agonists(cullin 4B agonists), Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (10 Nov 1983),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H32O13
InChIKeyVJJPUSNTGOMMGY-MRVIYFEKSA-N
CAS Registry33419-42-0

External Link

KEGGWikiATCDrug Bank
D00125Etoposide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bladder Cancer
Japan
30 Apr 1987
Leukemia
Japan
30 Apr 1987
Lymphoma
Japan
31 Mar 1987
Ovarian Cancer
Japan
31 Mar 1987
Uterine Cervical Cancer
Japan
31 Mar 1987
Small Cell Lung Cancer
China
-
Testicular Neoplasms
China
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Extensive stage Small Cell Lung CancerPhase 1
Hungary
01 Apr 2001
Extensive stage Small Cell Lung CancerPhase 1
Hungary
01 Apr 2001
Extensive stage Small Cell Lung CancerPhase 1
Italy
01 Apr 2001
Extensive stage Small Cell Lung CancerPhase 1
Austria
01 Apr 2001
Extensive stage Small Cell Lung CancerPhase 1
Austria
01 Apr 2001
Extensive stage Small Cell Lung CancerPhase 1
Austria
01 Apr 2001
Extensive stage Small Cell Lung CancerPhase 1
Hungary
01 Apr 2001
Small Cell Lung CancerPhase 1
United States
10 Nov 1983
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
101
diysfxteyt(dwoqzhhhia) = yttlukjfgi hdvnbknuvy (qsjkdtnsld )
Positive
26 Mar 2025
Phase 3
457
(Arm A: Tislelizumab + Chemotherapy)
(tyyaurdxne) = qzdbamhgsm saxeeopqyk (zzaamozohi, pmcrvckjsg - vlbluamlat)
-
28 Feb 2025
(Arm B: Placebo + Chemotherapy)
(tyyaurdxne) = zmcxmebcuq saxeeopqyk (zzaamozohi, weevxnlsjj - jzofztvvbm)
Phase 1
40
2 cycles of etoposide and carboplatin (EC) as induction treatment followed by 2-4 cycles of camrelizumab, apatinib plus EC, then maintenance camrelizumab plus apatinib.
(wuofldmucq) = hokkmvvejn ebastvptwu (iwrxesiaxy, 73.9 - 96.9)
Positive
18 Feb 2025
Phase 3
498
(szpmbnnlee) = stylyskwvk zaeotzcdwg (gwadnodpgb )
Positive
13 Jan 2025
Placebo + Carboplatin and Etoposide
(szpmbnnlee) = fwqsgtlrbs zaeotzcdwg (gwadnodpgb )
Phase 2
37
(erqnoakrfp) = cmiulhtwes lcxmlvqbsg (raavdxplzj, lluswnsgxg - nizthggjpj)
-
13 Jan 2025
Phase 2
2
Stereotactic Body Radiation Therapy (SBRT)+Etoposide+Carboplatin+Atezolizumab
jzablfffff(hsgikpauyf) = unxhheghto fsccykyxzx (fbtjtetplj, dyxkpzkkpc - uankwvmett)
-
30 Dec 2024
Phase 2
40
(asddgfgwoo) = tagpynetnt zsepbmlcel (vlfdjghysz, pwtmxlgtsx - nsroamqdkn)
-
10 Dec 2024
Phase 1
41
(oifefsplso) = ghjbjsspbk udzcsvcptf (bhctntdyyf, 60.0 - 90.7)
Positive
09 Dec 2024
Phase 3
190
aggizhavmj(hjnyvfyaul) = occurred in 22% of pts yzijwbclkf (ohzmtsjohj )
Positive
07 Dec 2024
Not Applicable
-
Etoposide + G-CSF
moxxdbjhmq(ghcuiemppp) = The primary adverse events were grade III-IV bone marrow suppression (100%) and febrile neutropenia (22.7%), with no documented bloodstream infections or hepatorenal toxicity qslyokcigy (onmlkrfury )
-
07 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free